Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Saturday 31.10.2020 at 7:00 AM CET
Settings

Settings

Goto Application

1. WO2016137825 - MILLICAPSULE FORMULATIONS COMPRISING POLYUNSATURATED FREE FATTY ACIDS

Publication Number WO/2016/137825
Publication Date 01.09.2016
International Application No. PCT/US2016/018571
International Filing Date 19.02.2016
IPC
A61K 9/14 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders
CPC
A61K 2300/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
2300Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
A61K 31/135
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines
135having aromatic rings ; , e.g. ketamine, nortriptyline
A61K 31/202
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
19Carboxylic acids, e.g. valproic acid
20having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
202having three or more double bonds, e.g. linolenic
A61K 9/4808
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
4808characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
A61K 9/4825
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
4816Wall or shell material
4825Proteins, e.g. gelatin
A61K 9/4833
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
4833Encapsulating processes; Filling of capsules
Applicants
  • OMTHERA PHARMACEUTICALS INC [US]/[US]
Inventors
  • KUBOTA, Hironori
  • ROGEAU, Etienne, Thierry, Charles
  • AMEMIYA, Toru
  • MEISSONNIER, Julien, Georges
  • HOLMÉN, Anders, Gillis
  • RADEVIK, Andreas
  • CARLSSON, Hans
  • SCHANTZ, Bengt, Staffan
Agents
  • RICHMOND, Meaghan
Priority Data
15305278.223.02.2015EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) MILLICAPSULE FORMULATIONS COMPRISING POLYUNSATURATED FREE FATTY ACIDS
(FR) PRÉPARATIONS EN MILLI-CAPSULES COMPRENANT DES ACIDES GRAS POLYINSATURÉS LIBRES
Abstract
(EN)
Capsular dosage forms containing polyunsaturated fatty acid (PUFA) compositions are provided herein. In certain embodiments, unit dosage forms comprising a plurality of millicapsules containing a PUFA composition therein are provided as well as their methods of use and manufacture. In certain embodiments, capsular dosage forms are provided herein that include a unit dosage form comprising a plurality of millicapsules containing a polyunsaturated free fatty acid substantially in free acid form. In some embodiments, the PUFA composition is Epanova®.
(FR)
L'invention concerne des formes pharmaceutiques capsulaires qui contiennent des compositions d'acides gras polyinsaturés (PUFA). Dans certains modes de réalisation, des formes pharmaceutiques unitaires comportant une pluralité de milli-capsules contenant une composition PUFA sont fournies, ainsi que leurs procédés d'utilisation et de fabrication. Dans certains modes de réalisation, l'invention concerne des formes pharmaceutiques capsulaires qui comprennent une forme pharmaceutique unitaire comportant une pluralité de milli-capsules contenant un acide gras polyinsaturé libre sensiblement sous forme d'acide libre. Dans certains modes de réalisation, la composition PUFA est Epanova®.
Latest bibliographic data on file with the International Bureau